<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bankhead, Charles</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Miravitlles, Marc</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Comorbidity Burden in Clinical Trials versus Clinical Practice</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2010</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2010-06-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">9-9</style></pages><abstract><style  face="normal" font="default" size="100%">Epidemiological studies have documented a high prevalence of comorbid conditions among patients who have chronic obstructive pulmonary disease (COPD), including hypertension, ischemic heart disease, hypercholesterolemia, diabetes, and anxiety and depression [Barr RG et al. Am J Med 2009; Carrasco-Garrido P et al. BMC Pulm Med 2009; Finkelstein J et al. Int J COPD 2009]. The epidemiological data underscore the need to know whether clinical trial results have come from studies that adequately represent the comorbidities of COPD patients.</style></abstract><number><style face="normal" font="default" size="100%">3</style></number><volume><style face="normal" font="default" size="100%">10</style></volume></record></records></xml>